[1] Ott JJ,Stevens GA,Groeger J,et al.Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine,2012,30(12):2212-2219. [2] He H,Zhou Y,Xie S.Assessment of the duplicate notifiable reporting of hepatitis B infection in Zhejiang province,China,2005-2015. Vaccine,2017,35(36):4702-4706. [3] Loomba R,Liang TJ.Hepatitis B reactivation associated with immune suppressive and biological modifier therapies:current concepts,management strategies,and future directions. Gastroenterology,2017,152(6):1297-1309. [4] 乔艳. 慢性乙型肝炎的免疫治疗研究进展. 实用肝脏病杂志,2016,19(4):493-496. [5] Shabani Z,Bagheri M,Zare-Bidaki M,et al.NK cells in hepatitis B virus infection:a potent target for immunotherapy. Arch Virol,2014,159(7):1555-1565. [6] Stojanovic A,Correia MP,Cerwenka A.The NKG2D/NKG2DL axis in the crosstalk between lymphoid and myeloid cells in health and disease. Front Immunol,2018,9:827. [7] Liu F,Duan X,Wan Z,et al.Lower number and decreased function of natural killer cells in hepatitis B virus related acute-on-chronic liver failure. Clin Res Hepatol Gastroenterol,2016,40(5):605-613. [8] Koumbi L,Pollicino T,Raimondo G,et al.Hepatitis B viral replication influences the expression of natural killer cell ligands. Ann Gastroenterol,2016,29(3):348-357. [9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ. [10] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南.实用肝脏病杂志,2013,16(3):210-216. [11] Lu FM,Zhuang H.Management of hepatitis B in China. Chin Med J (Engl),2009,122(1):3-4. [12] Schweitzer A,Horn J,Mikolajczyk RT,et al.Estimations of worldwide prevalence of chronic hepatitis B virus infection:a systematic review of data published between 1965 and 2013. Lancet,2015,386(10003):1546-1555. [13] Koehl U,Kalberer C,Spanholtz J,et al.Advances in clinical NK cell studies:Donor selection,manufacturing and quality control. Oncoimmunology,2016,5(4):e1115178. [14] Ferrari de Andrade L,Tay RE. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Hepatology,2018,59(6383):1537-1542. [15] Jelencic V,Lenartic M,Wensveen FM,et al.NKG2D:A versatile player in the immune system. Immunol Lett,2017,189:48-53. [16] Al Dulaimi D,Klibi J,Olivo Pimentel V,et al.Critical contribution of NK group 2 member D expressed on invariant natural killer t cells in concanavalin a-induced liver hepatitis in mice. Front Immunol,2018,9:1052. [17] Chen T,Zhu L,Shi A,et al.Functional restoration of CD56(bright) NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B. Hepatol Int,2017,11(5):419-428. [18] Zhang C,Wang Y,Zhou Z,et al.Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother,2009,58(8):1275-1285. [19] Wang Y,Wang W,Shen C, et al.NKG2D modulates aggravation of liver inflammation by activating NK cells in HBV infection. Sci Rep,2017,7(1): 88. [20] Chen T,Zhu L,Zhou Y,et al.KCTD9 contributes to liver injury through NK cell activation during hepatitis B virus-induced acute-on-chronic liver failure. Clin Immunol,2013,146(3):207-216. [21] Shabir S,Smith H,Kaul B,et al.Cytomegalovirus-associated CD4(+) CD28(null) cells in NKG2D-dependent glomerular endothelial injury and kidney allograft dysfunction. Am J Transplant,2016,16(4):1113-1128. [22] Farhadi N,Lambert L,Triulzi C,et al. Natural killer cell NKG2D and granzyme B are critical for allergic pulmonary inflammation. J Allergy Clin Immunol,2014,133(3):827-835.e823. [23] Li Y,Wang JJ,Gao S,et al.Decreased peripheral natural killer cells activity in the immune activated stage of chronic hepatitis B. PLoS One,2014,9(2):e86927. |